Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.980
+0.030 (1.54%)
At close: Mar 6, 2026, 4:00 PM EST
1.950
-0.030 (-1.52%)
After-hours: Mar 6, 2026, 6:44 PM EST
Company Description
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephan Jackman |
Contact Details
Address: 3480 Peachtree Road NE, Second Floor, Suite 103 Atlanta, Georgia 30326 United States | |
| Phone | 844 722 6333 |
| Website | alzamend.com |
Stock Details
| Ticker Symbol | ALZN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 1677077 |
| CUSIP Number | 02262M605 |
| ISIN Number | US02262M6057 |
| Employer ID | 81-1822909 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Milton Charles Ault III | Founder and Vice Chairman |
| Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | 424B5 | Filing |
| Mar 6, 2026 | 8-K | Current Report |
| Feb 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 26, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Dec 9, 2025 | 10-Q | Quarterly Report |
| Nov 18, 2025 | 8-K | Current Report |
| Oct 14, 2025 | 8-K | Current Report |
| Oct 9, 2025 | 8-K | Current Report |
| Oct 7, 2025 | SCHEDULE 13D/A | Filing |